PPARGC1A and melanoma: While MITF has been shown to antagonize pro-inflammatory responses through inhibition of NF-κB and AP-1 in melanoma (Riesenberg et al, 2015), we did not observe a reduction in MITF and PGC-1α transcript in MeWo cells treated with the RSK/PLK1 inhibitor BI-D1870.